drugset / Trial / NCT02183506

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

NCT02183506

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Investigate the bioavailability of BI 1356 BS and of metformin after concomitant multiple oral administration of 10 mg BI 1356 BS tablets and 3 x 850 mg metformin in comparison to BI 1356 BS and metformin given alone

Timeline

Start
2005-09
Primary completion
2005-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 10 mg Oral
Subject Metformin Small molecule 850 mg Oral

Indications

No indication recorded.